Elina Urpilainen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elina Urpilainen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Ulla Puistola
Department of Obstetrics and Gynecology, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, and University of Oulu, Oulu, Finland
5 shared publicationsAnne Ahtikoski
Department of Pathology, Fimlab Laboratories, University of Tampere, Tampere, Finland
3 shared publicationsPeeter Karihtala
Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
3 shared publications- Reijo Sund
University of Eastern Finland
3 shared publications - Ari Hautakoski
Research Unit of Clinical Medicine, University of Oulu, 90220 Oulu, Finland
2 shared publications - Martti Arffman
Department of Health and Social Care Systems, National Institute for Health and Welfare, Helsinki, Finland
2 shared publications
Latest Publications
- 17 June 2026
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
Chemotherapy and Palliative Care at the End of Life in Patients With Ovarian and Endometrial Cancer: A Retrospective Study
Background: Gynecological cancers are among the leading causes of cancer-related deaths, which makes it important to focus on the end-of-life (EOL) quality and its improvement among gynecological cancer patients. Several indirect indicators have been developed to assess poor EOL quality among gynecological cancer patients, and these indicators can be used to assess EOL quality across different settings. Objectives: (1) To assess the EOL quality and its improvement; and (2) to assess the EOL care and its changes among gynecological cancer patients at Oulu University Hospital by quality care measures. Design: We conducted a retrospective study, comparing 2 cohorts. Patient data were obtained from the records of Oulu University Hospital. Setting/Subjects: We compared 2 cohorts of gynecological cancer patients who died between 1.1.2018 and 30.6.2020 (Cohort 1) and between 1.1.2021 and 30.6.2023 (Cohort 2). Results: In the latter cohort (Cohort 2), more patients were referred to palliative care (81% vs 94%, respectively). Additionally, there was a significant decrease in the proportion of patients receiving chemotherapy during the last 3 months of life in Cohort 2 (44% vs 25%). The time between the EOL discussion and death was longer in Cohort 2 (median 57 vs 125 days, respectively). Conclusion: Based on these indicators, the EOL quality of patients with gynecological cancer at Oulu University Hospital may have improved in recent years. However, there remains room for improvement, particularly in the earlier initiation of palliative care.
- 17 June 2026
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
Chemotherapy and Palliative Care at the End of Life in Patients With Ovarian and Endometrial Cancer: A Retrospective Study
Background: Gynecological cancers are among the leading causes of cancer-related deaths, which makes it important to focus on the end-of-life (EOL) quality and its improvement among gynecological cancer patients. Several indirect indicators have been developed to assess poor EOL quality among gynecological cancer patients, and these indicators can be used to assess EOL quality across different settings. Objectives: (1) To assess the EOL quality and its improvement; and (2) to assess the EOL care and its changes among gynecological cancer patients at Oulu University Hospital by quality care measures. Design: We conducted a retrospective study, comparing 2 cohorts. Patient data were obtained from the records of Oulu University Hospital. Setting/Subjects: We compared 2 cohorts of gynecological cancer patients who died between 1.1.2018 and 30.6.2020 (Cohort 1) and between 1.1.2021 and 30.6.2023 (Cohort 2). Results: In the latter cohort (Cohort 2), more patients were referred to palliative care (81% vs 94%, respectively). Additionally, there was a significant decrease in the proportion of patients receiving chemotherapy during the last 3 months of life in Cohort 2 (44% vs 25%). The time between the EOL discussion and death was longer in Cohort 2 (median 57 vs 125 days, respectively). Conclusion: Based on these indicators, the EOL quality of patients with gynecological cancer at Oulu University Hospital may have improved in recent years. However, there remains room for improvement, particularly in the earlier initiation of palliative care.
- Open Access
- 24 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1654
The Association of Metformin, Other Antidiabetic Medications, and Statins with the Prognosis of Hepatocellular Carcinoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study
This study aimed to explore whether the prediagnostic use of metformin and statins is associated with the prognosis of patients with hepatocellular carcinoma (HCC) and type 2 diabetes. We identified 1383 eligible individuals who had both type 2 diabetes and HCC diagnosed between 1998 and 2017 from several Finnish registers. Cox models were fitted for cause-specific and all-cause mortality in relation to the use of antidiabetic medications and statins prior to the HCC diagnosis. Prediagnostic metformin use was associated with decreased overall mortality (hazard ratio 0.84, 95% confidence interval 0.74–0.94) compared with nonuse in patients with type 2 diabetes. Similarly, slightly decreased HCC mortality and other-cause mortality were observed among metformin users. The results were inconclusive regarding metformin use and both overall and HCC mortality among patients with localized HCC. No discernible contrast between statin users and nonusers was found in overall mortality nor HCC mortality in either the whole cohort or patients with localized cancer.
- 24 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1654
Open AccessThe Association of Metformin, Other Antidiabetic Medications, and Statins with the Prognosis of Hepatocellular Carcinoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study
This study aimed to explore whether the prediagnostic use of metformin and statins is associated with the prognosis of patients with hepatocellular carcinoma (HCC) and type 2 diabetes. We identified 1383 eligible individuals who had both type 2 diabetes and HCC diagnosed between 1998 and 2017 from several Finnish registers. Cox models were fitted for cause-specific and all-cause mortality in relation to the use of antidiabetic medications and statins prior to the HCC diagnosis. Prediagnostic metformin use was associated with decreased overall mortality (hazard ratio 0.84, 95% confidence interval 0.74–0.94) compared with nonuse in patients with type 2 diabetes. Similarly, slightly decreased HCC mortality and other-cause mortality were observed among metformin users. The results were inconclusive regarding metformin use and both overall and HCC mortality among patients with localized HCC. No discernible contrast between statin users and nonusers was found in overall mortality nor HCC mortality in either the whole cohort or patients with localized cancer.
- Open Access
- 8 July 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1393103
Redox-state-regulating enzymes have prognostic value in diabetic endometrial cancer patients: impact of statin use?
Objective: The incidence of endometrial cancer is increasing, and oxidative stress has been suggested to play a vital role in its carcinogenesis. Statins have an impact on the cellular redox-state. The aim of this study was to determine the effects of statin use on redox-state regulating enzymes in endometrial cancer in women with type 2 diabetes.Materials and methods: This retrospective study consisted of 119 women with type 2 diabetes who were diagnosed with endometrial cancer at Oulu University Hospital in Finland between 2007 and 2014. There were 58 statin users and 61 non-users based on medication use at the time of endometrial cancer diagnosis. The expression of redox-state regulating proteins nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) in the tumor samples was assessed immunohistochemically, and manganese superoxide dismutase (MnSOD) levels were measured both immunohistochemically and from serum samples.Results: High MnSOD expression predicted better progression-free survival (PFS) in statin non-users in a univariate analysis (p=0.02). There was no statistical difference in overall survival (OS) or PFS between strong and weak expression of Nrf2 and Keap1. After adjusting for stage and statin use, the results were similar.Conclusion: Statin non-users with strong MnSOD expression had better PFS compared to statin users which proves that statins have impact on redox-state regulating enzymes. However, these findings are preliminary and require further research.
- 8 July 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1393103
Open AccessRedox-state-regulating enzymes have prognostic value in diabetic endometrial cancer patients: impact of statin use?
Objective: The incidence of endometrial cancer is increasing, and oxidative stress has been suggested to play a vital role in its carcinogenesis. Statins have an impact on the cellular redox-state. The aim of this study was to determine the effects of statin use on redox-state regulating enzymes in endometrial cancer in women with type 2 diabetes.Materials and methods: This retrospective study consisted of 119 women with type 2 diabetes who were diagnosed with endometrial cancer at Oulu University Hospital in Finland between 2007 and 2014. There were 58 statin users and 61 non-users based on medication use at the time of endometrial cancer diagnosis. The expression of redox-state regulating proteins nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) in the tumor samples was assessed immunohistochemically, and manganese superoxide dismutase (MnSOD) levels were measured both immunohistochemically and from serum samples.Results: High MnSOD expression predicted better progression-free survival (PFS) in statin non-users in a univariate analysis (p=0.02). There was no statistical difference in overall survival (OS) or PFS between strong and weak expression of Nrf2 and Keap1. After adjusting for stage and statin use, the results were similar.Conclusion: Statin non-users with strong MnSOD expression had better PFS compared to statin users which proves that statins have impact on redox-state regulating enzymes. However, these findings are preliminary and require further research.
- Open Access
- 30 August 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (9) , 4037-4043
Immunological Markers ofChlamydia trachomatisInfection in Epithelial Ovarian Cancer
Background/Aim: Pelvic inflammatory disease (PID) is a risk factor for epithelial ovarian cancer (EOC). Chlamydia trachomatis infection, a major cause of PID, may persist in some women. Serum IgG antibodies to chlamydial TroA and HtrA are more common in ascending or repeat chlamydial infection than in uncomplicated infection. The aim of this study was to explore the role of C. trachomatis infection in EOC by analyzing chlamydial TroA, HtrA and major outer membrane protein (MOMP) IgG serum antibody responses. Patients and Methods: The study is based on the review of Oulu University Hospital medical records of 162 women diagnosed with EOC between March 2008 and May 2018. Serum IgG antibody responses to recombinant C. trachomatis TroA, HtrA and MOMP were analyzed using enzyme-linked immunoassay. Complete response to the first line therapy and the three-year survival were the study endpoints. Results: Altogether, 16.7%, 11.1% and 12.3% women were C. trachomatis TroA, HtrA and MOMP IgG positive, respectively. Women with these antibodies were more likely to have a complete response to the first-line treatment, compared to women without these antibodies (63.0% vs. 34.1% for TroA IgG, 50.0% vs. 37.5% for HtrA IgG and 50% vs. 37.3% for MOMP IgG, respectively). The presence of these antibodies predicted better three-year survival. Conclusion: Women with EOC and positive markers of persistent C. trachomatis infection have better response to the first-line treatment and seem to have better three-year survival.
- 30 August 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (9) , 4037-4043
Open AccessImmunological Markers ofChlamydia trachomatisInfection in Epithelial Ovarian Cancer
Background/Aim: Pelvic inflammatory disease (PID) is a risk factor for epithelial ovarian cancer (EOC). Chlamydia trachomatis infection, a major cause of PID, may persist in some women. Serum IgG antibodies to chlamydial TroA and HtrA are more common in ascending or repeat chlamydial infection than in uncomplicated infection. The aim of this study was to explore the role of C. trachomatis infection in EOC by analyzing chlamydial TroA, HtrA and major outer membrane protein (MOMP) IgG serum antibody responses. Patients and Methods: The study is based on the review of Oulu University Hospital medical records of 162 women diagnosed with EOC between March 2008 and May 2018. Serum IgG antibody responses to recombinant C. trachomatis TroA, HtrA and MOMP were analyzed using enzyme-linked immunoassay. Complete response to the first line therapy and the three-year survival were the study endpoints. Results: Altogether, 16.7%, 11.1% and 12.3% women were C. trachomatis TroA, HtrA and MOMP IgG positive, respectively. Women with these antibodies were more likely to have a complete response to the first-line treatment, compared to women without these antibodies (63.0% vs. 34.1% for TroA IgG, 50.0% vs. 37.5% for HtrA IgG and 50% vs. 37.3% for MOMP IgG, respectively). The presence of these antibodies predicted better three-year survival. Conclusion: Women with EOC and positive markers of persistent C. trachomatis infection have better response to the first-line treatment and seem to have better three-year survival.
- Open Access
- 13 May 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
No Association Between Statin Use and the Prognosis of Endometrial Cancer in Women With Type 2 Diabetes
Preclinical studies have suggested statins have antiproliferative and anti-metastatic effects on endometrial cancer cells. Similarly, most previous epidemiological studies have reported a better prognosis of endometrial cancer in patients who used statins. In this study, we explored the role of statins in the prognosis of endometrial cancer in women with type 2 diabetes in a hospital-based cohort. This retrospective cohort consisted of 119 women with type 2 diabetes who were diagnosed and treated for endometrial cancer at Oulu University Hospital, Finland, between 2007 and 2014. The patients were classified as statin users (n = 58) and nonusers (n = 61) based on the type of medication they were using at the time of endometrial cancer diagnosis. Statin use showed no association with progression-free survival or overall survival in the whole cohort nor the subgroups with type I or type II histology, in lower or higher body mass index groups, or at an early or advanced stage. The results remained similar in the multivariate analysis after adjusting for the patient’s age, cancer stage, and histology. Furthermore, statin use seemed not to have any association with most of the prognostic factors at the time of endometrial cancer diagnosis.
- 13 May 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessNo Association Between Statin Use and the Prognosis of Endometrial Cancer in Women With Type 2 Diabetes
Preclinical studies have suggested statins have antiproliferative and anti-metastatic effects on endometrial cancer cells. Similarly, most previous epidemiological studies have reported a better prognosis of endometrial cancer in patients who used statins. In this study, we explored the role of statins in the prognosis of endometrial cancer in women with type 2 diabetes in a hospital-based cohort. This retrospective cohort consisted of 119 women with type 2 diabetes who were diagnosed and treated for endometrial cancer at Oulu University Hospital, Finland, between 2007 and 2014. The patients were classified as statin users (n = 58) and nonusers (n = 61) based on the type of medication they were using at the time of endometrial cancer diagnosis. Statin use showed no association with progression-free survival or overall survival in the whole cohort nor the subgroups with type I or type II histology, in lower or higher body mass index groups, or at an early or advanced stage. The results remained similar in the multivariate analysis after adjusting for the patient’s age, cancer stage, and histology. Furthermore, statin use seemed not to have any association with most of the prognostic factors at the time of endometrial cancer diagnosis.
- 30 January 2021
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (2) , 821-828
Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes
Background/Aim: Preclinical studies on metformin use and endometrial cancer have been promising but epidemiological studies have reported variable results. This study aimed to assess if metformin use is associated with endometrial cancer aggressiveness and survival in women with type 2 diabetes (T2D). Patients and Methods: This retrospective hospital-based cohort consisted of women with T2D who were treated for endometrial cancer at the Oulu University Hospital, Finland, between 2007 and 2014. Results: The sample size was 121 patients: 58 metformin users and 63 metformin non-users. Intriguingly, type 2 histology, deep myometrial invasion and the presence of lymphovascular invasion were more common in the metformin user group. However, metformin use showed no association with overall survival and progression-free survival. Conclusion: Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D.
- 30 January 2021
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (2) , 821-828
Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes
Background/Aim: Preclinical studies on metformin use and endometrial cancer have been promising but epidemiological studies have reported variable results. This study aimed to assess if metformin use is associated with endometrial cancer aggressiveness and survival in women with type 2 diabetes (T2D). Patients and Methods: This retrospective hospital-based cohort consisted of women with T2D who were treated for endometrial cancer at the Oulu University Hospital, Finland, between 2007 and 2014. Results: The sample size was 121 patients: 58 metformin users and 63 metformin non-users. Intriguingly, type 2 histology, deep myometrial invasion and the presence of lymphovascular invasion were more common in the metformin user group. However, metformin use showed no association with overall survival and progression-free survival. Conclusion: Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D.
- Open Access
- 11 January 2019
- Published by SAGE Publications in Tumor Biology
- Vol. 41 (1)
Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a major regulator of the oxidative stress response and it is negatively regulated by Kelch-like ECH-associated protein 1 (Keap1). The Keap1–Nrf2 axis has a fundamental role in carcinogenesis. In previous studies, the widely used diabetes drug metformin has appeared to have a critical role in the regulation of Nrf2 function. In this study, we assessed the expression of Nrf2 and Keap1 immunohistochemically in 157 patients with type 2 diabetes who underwent breast cancer surgery with curative intent. In total, 78 (49.7%) of these patients were taking metformin alone or combined with other oral anti-diabetic medication at the time of breast cancer diagnosis. We found that high-level cytoplasmic Nrf2 expression predicted dismal overall survival and breast cancer–specific survival, but only in the patients who were not taking metformin at the time of diagnosis. Similarly, low-level nuclear Keap1 expression had an adverse prognostic value in terms of overall survival and breast cancer–specific survival in patients without metformin. On the other hand, high-level nuclear Keap1 expression was associated with prolonged overall survival and breast cancer–specific survival. The results may be explained in terms of non-functioning or displaced Keap1, although more mechanistic pre-clinical and prospective clinical studies are warranted.
- 11 January 2019
- Published by SAGE Publications in Tumor Biology
- Vol. 41 (1)
Open AccessMetformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a major regulator of the oxidative stress response and it is negatively regulated by Kelch-like ECH-associated protein 1 (Keap1). The Keap1–Nrf2 axis has a fundamental role in carcinogenesis. In previous studies, the widely used diabetes drug metformin has appeared to have a critical role in the regulation of Nrf2 function. In this study, we assessed the expression of Nrf2 and Keap1 immunohistochemically in 157 patients with type 2 diabetes who underwent breast cancer surgery with curative intent. In total, 78 (49.7%) of these patients were taking metformin alone or combined with other oral anti-diabetic medication at the time of breast cancer diagnosis. We found that high-level cytoplasmic Nrf2 expression predicted dismal overall survival and breast cancer–specific survival, but only in the patients who were not taking metformin at the time of diagnosis. Similarly, low-level nuclear Keap1 expression had an adverse prognostic value in terms of overall survival and breast cancer–specific survival in patients without metformin. On the other hand, high-level nuclear Keap1 expression was associated with prolonged overall survival and breast cancer–specific survival. The results may be explained in terms of non-functioning or displaced Keap1, although more mechanistic pre-clinical and prospective clinical studies are warranted.
- Open Access
- 28 July 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study
Ovarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even poorer survival from it. We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with metformin, other forms of antidiabetic medication, or statins. Study cohort consisted of women with T2D diagnosed with ovarian cancer in Finland 1998–2011. They were identified from a nationwide diabetes database (FinDM), being linked to several national registers. Patients were grouped according to their medication in the three years preceding ovarian cancer diagnosis. The Aalen–Johansen estimator was used to describe cumulative mortality from ovarian cancer and from other causes in different medication groups. Mortality rates were analysed by Cox models, and adjusted hazard ratios (HR) with 95% confidence intervals (95% CIs) were estimated in relation to the use of different forms of medication. Main outcome measures were death from ovarian cancer and death from other causes. During the accrual period 421 newly diagnosed ovarian cancers were identified in the FinDM database. No evidence was found for any differences in mortality from ovarian cancer or other causes between different antidiabetic medication groups. Pre-diagnostic use of statins was observed to be associated with decreased mortality from ovarian cancer compared with no such use (HR 0.72, 95% CI 0.56–0.93). Our findings are inconclusive as regards the association between metformin and ovarian cancer survival. However, some evidence was found for improved prognosis of ovarian cancer with pre-diagnostic statin use, requiring cautious interpretation, though.
- 28 July 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Open AccessPrognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study
Ovarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even poorer survival from it. We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with metformin, other forms of antidiabetic medication, or statins. Study cohort consisted of women with T2D diagnosed with ovarian cancer in Finland 1998–2011. They were identified from a nationwide diabetes database (FinDM), being linked to several national registers. Patients were grouped according to their medication in the three years preceding ovarian cancer diagnosis. The Aalen–Johansen estimator was used to describe cumulative mortality from ovarian cancer and from other causes in different medication groups. Mortality rates were analysed by Cox models, and adjusted hazard ratios (HR) with 95% confidence intervals (95% CIs) were estimated in relation to the use of different forms of medication. Main outcome measures were death from ovarian cancer and death from other causes. During the accrual period 421 newly diagnosed ovarian cancers were identified in the FinDM database. No evidence was found for any differences in mortality from ovarian cancer or other causes between different antidiabetic medication groups. Pre-diagnostic use of statins was observed to be associated with decreased mortality from ovarian cancer compared with no such use (HR 0.72, 95% CI 0.56–0.93). Our findings are inconclusive as regards the association between metformin and ovarian cancer survival. However, some evidence was found for improved prognosis of ovarian cancer with pre-diagnostic statin use, requiring cautious interpretation, though.
- 7 February 2018
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 125 (8) , 1001-1008
The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study
Objective: To obtain evidence of the effects of metformin and statins on the incidence of ovarian cancer in women with type 2 diabetes (T2D).Design: A retrospective cohort study and nested case–control study.Setting: The data were obtained from a diabetes database (FinDM) combining information from several nationwide registers.Population: A cohort of 137 643 women over 40 years old and diagnosed with T2D during 1996–2011 in Finland.Methods: In full cohort analysis Poisson regression was used to estimate the hazard ratios (HR) in relation to ever use of metformin, insulin other oral anti‐diabetic medication or statins. In the nested case–control analysis 20 controls were matched to each case of ovarian cancer. Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different medications. The estimates were adjusted for age and duration of T2D.Main outcome measure: Incidence of ovarian cancer.Results: In all, 303 women were diagnosed with ovarian cancer during the follow up. Compared with other forms of oral anti‐diabetic medication, metformin (HR 1.02, 95% CI: 0.72–1.45) was not found to be associated with the incidence of ovarian cancer. Neither was there evidence for statins to affect the incidence (HR 0.99, 95% CI: 0.78–1.25). In nested case–control analysis the results were essentially similar.Conclusions: No evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in women with T2D was found.Tweetable No evidence found for metformin or statins reducing the incidence of ovarian cancer.
- 7 February 2018
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 125 (8) , 1001-1008
The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study
Objective: To obtain evidence of the effects of metformin and statins on the incidence of ovarian cancer in women with type 2 diabetes (T2D).Design: A retrospective cohort study and nested case–control study.Setting: The data were obtained from a diabetes database (FinDM) combining information from several nationwide registers.Population: A cohort of 137 643 women over 40 years old and diagnosed with T2D during 1996–2011 in Finland.Methods: In full cohort analysis Poisson regression was used to estimate the hazard ratios (HR) in relation to ever use of metformin, insulin other oral anti‐diabetic medication or statins. In the nested case–control analysis 20 controls were matched to each case of ovarian cancer. Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different medications. The estimates were adjusted for age and duration of T2D.Main outcome measure: Incidence of ovarian cancer.Results: In all, 303 women were diagnosed with ovarian cancer during the follow up. Compared with other forms of oral anti‐diabetic medication, metformin (HR 1.02, 95% CI: 0.72–1.45) was not found to be associated with the incidence of ovarian cancer. Neither was there evidence for statins to affect the incidence (HR 0.99, 95% CI: 0.78–1.25). In nested case–control analysis the results were essentially similar.Conclusions: No evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in women with T2D was found.Tweetable No evidence found for metformin or statins reducing the incidence of ovarian cancer.